Bio-Techne Acquires Single-Cell Company
Dr. Gardner told IBO that Zephyrus had six full-time employees. The Z1 is available to early access customers. “Key applications that it enables include measuring intracellular proteins that cannot be measured with flow cytometry, providing protein-level validation of single-cell RNAseq experiments, and identifying subpopulations of cells that cannot be resolved with conventional western blotting.”
Minneapolis, MN 3/31/16—Bio-Techne has purchased Zephyrus Biosciences for an undisclosed amount. Zephyrus’s Z1 System is designed for western blotting of individual cells. “This new technology brings this technique to the single-cell level, allowing us to address both homogeneous sample populations with our Simple Western platforms and now heterogeneous populations at the single-cell level with Zephyrus and the Z1 System,” stated Bio-Techne President and CEO Charles R. Kummeth. Zephyrus will join Bio-Techne’s Protein Platforms Division. Zephyrus Cofounder and CEO Kelly Gardner, PhD, and other employees will remain with the company.
